Medindia LOGIN REGISTER
Medindia

Latest Publications and Research on Constipation-Symptom Evaluation

Dig. Dis. Sci.   2020 Feb 01   

Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation.

DuPont HL, Jiang ZD, DuPont AW, Utay NS

Reduction in diversity of the intestinal microbiome (dysbiosis) is being identified in many disease states, and studies are showing important biologic ... Read More

Source: PubMed
J Pediatr Urol   2019 Dec 27   

Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.

Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, Snijder R, Stroosma O, Verheggen F, Newgreen D, Bosman B, Vande Walle J

The standard recommended treatment for neurogenic detrusor overactivity (NDO) is clean intermittent catheterization combined with an antimuscarinic ag ... Read More

Source: PubMed
Clin Nutr   2020 Jan 14   

Meta-analysis of randomized controlled trials of the effects of probiotics on functional constipation in adults.

Zhang C, Jiang J, Tian F, Zhao J, Zhang H, Zhai Q, Chen W

Clinical trials have reported controversial results regarding the effectiveness of probiotics in alleviating functional constipation in adults. We rev ... Read More

Source: PubMed
Clin. Breast Cancer   2020 Jan 07   

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study.

Rashad N, Abdelhamid T, Shouman SA, Nassar H, Omran MA, El Desouky ED, Khaled H

Preclinical studies have suggested a synergistic effect of tamoxifen and capecitabine in estrogen receptor-positive cell lines. We evaluated the safet ... Read More

Source: PubMed
BMC Gastroenterol      

Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study.

Kamei D, Kamei Y, Nagano M, Mineshima M, Nitta K, Tsuchiya K

Hemodialysis patients are prone to constipation, which can adversely affect their quality of life (QOL). Elobixibat, a highly selective inhibitor of t ... Read More

Source: PubMed

Advertisement